Display options
Cite
Popova TV, Pyshnaya IA, Zakharova OD, et al. Rational Design of Albumin Theranostic Conjugates for Gold Nanoparticles Anticancer Drugs: Where the Seed Meets the Soil?. Biomedicines. 2021;9(1)doi: 10.3390/biomedicines9010074.
Popova, T. V., Pyshnaya, I. A., Zakharova, O. D., Akulov, A. E., Shevelev, O. B., Poletaeva, J., Zavjalov, E. L., Silnikov, V. N., Ryabchikova, E. I., & Godovikova, T. S. (2021). Rational Design of Albumin Theranostic Conjugates for Gold Nanoparticles Anticancer Drugs: Where the Seed Meets the Soil?. Biomedicines, 9(1), . https://doi.org/10.3390/biomedicines9010074
Popova, Tatyana V, et al. "Rational Design of Albumin Theranostic Conjugates for Gold Nanoparticles Anticancer Drugs: Where the Seed Meets the Soil?." Biomedicines vol. 9,1 (2021). doi: https://doi.org/10.3390/biomedicines9010074
Popova TV, Pyshnaya IA, Zakharova OD, Akulov AE, Shevelev OB, Poletaeva J, Zavjalov EL, Silnikov VN, Ryabchikova EI, Godovikova TS. Rational Design of Albumin Theranostic Conjugates for Gold Nanoparticles Anticancer Drugs: Where the Seed Meets the Soil?. Biomedicines. 2021 Jan 13;9(1). doi: 10.3390/biomedicines9010074. PMID: 33451058; PMCID: PMC7828547.
Copy Download .nbib Format: NLM
Share it on

Biomedicines. 2021 Jan 13;9(1). doi: 10.3390/biomedicines9010074.

Rational Design of Albumin Theranostic Conjugates for Gold Nanoparticles Anticancer Drugs: Where the Seed Meets the Soil?.

Biomedicines

Tatyana V Popova, Inna A Pyshnaya, Olga D Zakharova, Andrey E Akulov, Oleg B Shevelev, Julia Poletaeva, Evgenii L Zavjalov, Vladimir N Silnikov, Elena I Ryabchikova, Tatyana S Godovikova

Affiliations

  1. Institute of Chemical Biology and Fundamental Medicine, The Siberian Branch of the Russian Academy of Sciences, Lavrentiev ave. 8, 630090 Novosibirsk, Russia.
  2. Institute of Cytology and Genetics, SB RAS, Lavrentiev ave. 10, 630090 Novosibirsk, Russia.

PMID: 33451058 PMCID: PMC7828547 DOI: 10.3390/biomedicines9010074

Abstract

Multifunctional gold nanoparticles (AuNPs) may serve as a scaffold to integrate diagnostic and therapeutic functions into one theranostic system, thereby simultaneously facilitating diagnosis and therapy and monitoring therapeutic responses. Herein, albumin-AuNP theranostic agents have been obtained by conjugation of an anticancer nucleotide trifluorothymidine (TFT) or a boron-neutron capture therapy drug undecahydro-

Keywords: albumin theranostic conjugates; boronated albumin conjugate; fluorescence-based molecular imaging; gold nanoparticles; trifluorothymidine-albumin conjugate

References

  1. Matrix Biol. 2001 Jan;19(8):816-27 - PubMed
  2. Cancer Metastasis Rev. 2008 Dec;27(4):691-705 - PubMed
  3. Theranostics. 2015 Jan 21;5(4):357-70 - PubMed
  4. Colloids Surf B Biointerfaces. 2019 Nov 1;183:110387 - PubMed
  5. Chem Soc Rev. 2012 Apr 7;41(7):2885-911 - PubMed
  6. Biotechnol Adv. 2013 Sep-Oct;31(5):593-606 - PubMed
  7. J Control Release. 2012 Jan 30;157(2):168-82 - PubMed
  8. Cancer Commun (Lond). 2018 Jun 19;38(1):36 - PubMed
  9. Int J Nanomedicine. 2019 Aug 09;14:6387-6406 - PubMed
  10. Eur J Pharm Biopharm. 2011 Apr;77(3):417-23 - PubMed
  11. Dalton Trans. 2014 Apr 7;43(13):5054-61 - PubMed
  12. Curr Pharm Des. 2015;21(14):1889-98 - PubMed
  13. Bioorg Med Chem Lett. 2018 Feb 1;28(3):260-264 - PubMed
  14. NMR Biomed. 2011 Feb;24(2):114-29 - PubMed
  15. J Am Chem Soc. 2010 Apr 7;132(13):4678-84 - PubMed
  16. J Neurooncol. 2009 Jan;91(2):199-206 - PubMed
  17. Nanomaterials (Basel). 2013 Jan 31;3(1):86-106 - PubMed
  18. ChemMedChem. 2016 Aug 19;11(16):1840-9 - PubMed
  19. Int J Nanomedicine. 2017 Aug 22;12:6131-6152 - PubMed
  20. Bioorg Med Chem. 2015 Nov 1;23(21):6943-54 - PubMed
  21. J Neurosurg. 2005 Dec;103(6):1000-9 - PubMed
  22. Ther Deliv. 2013 Apr;4(4):421-3 - PubMed
  23. Chem Soc Rev. 2012 Jan 7;41(1):242-57 - PubMed
  24. Phys Med Biol. 2008 Dec 7;53(23):6979-89 - PubMed
  25. J Neurooncol. 2003 Mar-Apr;62(1-2):87-99 - PubMed
  26. J Immunol Methods. 1983 Dec 16;65(1-2):55-63 - PubMed
  27. Clin Cancer Res. 2010 Dec 15;16(24):6139-49 - PubMed
  28. Mol Pharm. 2013 Mar 4;10(3):831-47 - PubMed
  29. Biomaterials. 2014 Mar;35(10):3480-7 - PubMed
  30. Int J Biochem Cell Biol. 1999 Dec;31(12):1363-6 - PubMed
  31. Colloids Surf B Biointerfaces. 2008 Oct 15;66(2):274-80 - PubMed
  32. Biomaterials. 2014 Mar;35(10):3455-66 - PubMed
  33. Adv Drug Deliv Rev. 2013 May;65(5):663-76 - PubMed
  34. ACS Nano. 2016 Nov 22;10(11):9999-10012 - PubMed
  35. Mol Cell Ther. 2016 Feb 27;4:3 - PubMed
  36. Cancer Commun (Lond). 2018 Jun 19;38(1):35 - PubMed
  37. Clin Cancer Res. 2005 Jun 1;11(11):3987-4002 - PubMed
  38. J Drug Target. 2013 Jan;21(1):77-86 - PubMed
  39. Adv Colloid Interface Sci. 2017 Aug;246:13-39 - PubMed
  40. Bioorg Med Chem Lett. 2017 Aug 15;27(16):3925-3930 - PubMed
  41. Molecules. 2019 Oct 07;24(19): - PubMed
  42. Chem Commun (Camb). 2015 Feb 28;51(17):3634-6 - PubMed
  43. Oncogene. 2007 Jun 14;26(28):4084-94 - PubMed
  44. J Am Chem Soc. 2014 Jan 8;136(1):449-57 - PubMed
  45. Curr Pharm Des. 2016;22(35):5442-5462 - PubMed

Publication Types

Grant support